BULLETIN DU CANCER is a pivotal academic journal dedicated to the field of oncology, providing a platform for innovative research and insights into cancer treatment and diagnostics. Published by Elsevier Masson, Corp Off in France, this journal has been a part of the scientific community since 1966, and is committed to sharing critical findings that influence clinical practices and improve patient outcomes. Despite its recent rankings placing it in the Q4 category for Cancer Research and Q3 for Hematology and other related fields, BULLETIN DU CANCER remains essential for those interested in the latest developments in cancer biology and treatment methodologies. With an emphasis on both basic and clinical research, it serves as a valuable resource for researchers, healthcare professionals, and students seeking to deepen their understanding in various dimensions of oncology. This journal is particularly relevant as it continues to spotlight emerging research trends and supports the global imperative to combat cancer more effectively.

ONCOLOGIST is a premier, open-access journal published by Oxford University Press, advancing the field of cancer research since its inception in 1996. With an impressive H-Index and a prestigious placement within the Q1 category in Cancer Research, Medicine, and Oncology for 2023, ONCOLOGIST stands at the forefront of oncological science, boasting a Scopus rank of #55 out of 404 in Medicine and #47 out of 230 in Cancer Research. This journal not only disseminates cutting-edge research but also aims to foster multidisciplinary approaches that are critical for addressing the complex challenges faced in cancer therapy and survivorship. Be part of a vibrant community as you explore impactful research articles that contribute to the global conversation on cancer. ONCOLOGIST is dedicated to providing an accessible platform for authors and readers alike, ensuring that high-quality research is available to all stakeholders in the fight against cancer.

Journal of Cancer Policy is an esteemed publication devoted to the critical intersection of health policy and oncology. Published by Elsevier Sci Ltd in the United Kingdom, this journal has been a pivotal platform since its inception in 2013, contributing to the field's discourse on cancer management and policy-making strategies. With an impressive Q2 ranking in both the Health Policy and Oncology categories for 2023, it underscores its significance in shaping policy frameworks that address the complexities of cancer care. The journal is listed in Scopus with a respectable rank of #177 in Health Policy and #261 in Oncology, indicating its broad reach and impactful contributions to research and scholarly discussions. While the journal operates under a subscription model, it aims to provide readers with high-quality research that can influence health decisions and policy formation. As a vital resource for researchers, healthcare professionals, and students alike, the Journal of Cancer Policy plays a fundamental role in advancing the understanding of how policies can improve cancer outcomes and healthcare systems.

Cancer Management and Research, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to advancing the field of oncology. Since its inception in 2009, this journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals focused on cancer treatment and management. With its robust impact factor and impressive Scopus ranking in the 77th percentile of oncology medicine, it provides a prominent platform for sharing high-quality research. The journal covers a wide range of topics within cancer management, including innovative therapeutic strategies, clinical trials, patient care, and health policy, ensuring a comprehensive approach to current challenges in the field. Operating from New Zealand, it invites contributions that can shape the future of oncology and improve patient outcomes globally, making it an essential addition to the libraries of those engaged in cancer research and practice.

Healthcare Informatics Research, published by the Korean Society of Medical Informatics, is a leading open access journal that has been advancing the field of healthcare informatics since its inception in 2010. With an ISSN of 2093-3681 and E-ISSN of 2093-369X, the journal provides a vital platform for disseminating high-quality research aimed at improving healthcare systems through innovative informatics solutions. Recognized for its contributions, it holds a Q2 rank in Biomedical Engineering and Q3 rankings in both Health Informatics and Health Information Management for 2023, reflecting its stature within the academic community. The journal is committed to open access, ensuring that research is freely accessible to researchers, professionals, and students worldwide, thus promoting knowledge sharing and collaboration. Located in the dynamic city of Seoul, South Korea, the journal serves as a hub for groundbreaking studies that impact health systems globally, making it an essential resource for those at the forefront of healthcare technology and management.

BMC Primary Care is a leading peer-reviewed journal published by BMC that provides a vital platform for the dissemination of research and developments in the field of primary care. Established in 2022 as an open access journal, it allows for greater accessibility and visibility of research findings. Operating from the United Kingdom, BMC Primary Care has rapidly assumed an esteemed position within the academic community, currently ranked in the Q1 category for both Family Practice and Medicine (miscellaneous) based on 2023 metrics. With a Scopus rank of #9 out of 56 in Family Practice, positioned in the 84th percentile, this journal serves as an essential resource for researchers, healthcare practitioners, and students seeking to enhance their understanding of primary care dynamics. Through a commitment to high-quality research, BMC Primary Care aims to foster innovation and effective practices that ultimately improve patient care and health outcomes.

JCO Oncology Practice is a premier peer-reviewed journal published by Lippincott Williams & Wilkins, specializing in the intersection of oncology and health policy. Established as a vital resource since 2020, this journal serves as a platform for the dissemination of innovative research, policy analysis, and clinical practice advancements aimed at enhancing cancer care. With its impressive impact factor and recognition in the top quartile (Q1) across multiple categories including Health Policy and Oncology, JCO Oncology Practice ranks #3 in Oncology Nursing and consistently shares cutting-edge insights that drive improvements within the field. The journal is accessible to a broad audience through its open access options, ensuring that vital knowledge reaches practitioners, researchers, and students alike. By prioritizing the latest evidence-based practices and addressing contemporary challenges in cancer treatment, JCO Oncology Practice plays an essential role in shaping the future of oncology practice and policy in the United States and beyond.

Current Oncology is a prominent open-access journal dedicated to the field of oncology, published by MDPI in Switzerland. With an ISSN of 1198-0052 and E-ISSN 1718-7729, this esteemed journal has been providing valuable insights since its inception in 1998 and continues to publish cutting-edge research through 2024. Recognized for its contribution to the medical community, Current Oncology holds a 2023 Q2 category rank in Oncology and is positioned at the 41st percentile among its peers in Scopus rankings. As a hub for innovation and discussion in cancer research, it offers a plethora of articles that span various aspects of oncology, making it an essential resource for researchers, professionals, and students alike. Since becoming fully open-access in 2006, it provides expanded accessibility to groundbreaking studies and findings, fostering collaboration and knowledge exchange across the global research community. With its central location in Basel, Switzerland, Current Oncology plays a pivotal role in advancing oncology's frontiers.

Journal of Geriatric Oncology, published by Elsevier, stands at the intersection of geriatric medicine and oncology, addressing the unique needs and challenges of cancer management in older adults. Since its inception in 2010, this esteemed journal has played a pivotal role in advancing research and clinical practices, aiming to improve the quality of life and treatment outcomes for elderly cancer patients. With its impressive categorization in the 2023 Q2 quartile for both Geriatrics and Gerontology and Oncology, the journal demonstrates a noteworthy impact within its fields, ranking #153 out of 404 in Medicine – Oncology and #45 out of 116 in Medicine – Geriatrics and Gerontology. Researchers and healthcare professionals are encouraged to access critical insights through its rigorous peer-reviewed articles, which offer cutting-edge research findings and clinical applications. As the field continues to evolve, the Journal of Geriatric Oncology remains a vital resource for those dedicated to fostering innovation in geriatric oncology.

Medical Oncology, published by Humana Press Inc, stands as a significant contributor to the field of oncology, with its long-standing commitment to disseminating research and clinical findings relevant to the treatment and management of cancer. Established in 1994 and continuing through 2024, this journal publishes insightful articles that reflect the latest advancements in cancer research, hematology, and related medical fields. With an evolving impact factor and remarkable categorizations, including Q3 in Cancer Research and Q2 in both Hematology and Oncology, Medical Oncology serves as a pivotal resource for healthcare providers, researchers, and students dedicated to improving cancer outcomes. Although it does not offer open access, the journal is widely recognized for its rigorous peer-review process and high-quality publications, making it an essential platform for sharing innovative research and critical reviews in oncology.